COVID-19 Vaccinations: Evidence for Delaying-Second-Dose and Mix-and-Match Strategies ?
OrthoEvidence Journal (OE Journal) - OE Original
OE Journal. 2021;9(11):3The debate around delaying second doses and mixing COVID-19 vaccines grew out of urgent pandemic pressures, and the evidence has only recently started to catch up. Early data and modeling work suggested that a strong first-dose response, especially for mRNA vaccines, could meaningfully cut infections and hospitalizations, giving the delayed-dose strategy some credibility. At the same time, interest in mix-and-match schedules has expanded; early studies now point to good safety and striking antibody responses—particularly AstraZeneca-prime followed by Pfizer-boost—yet key comparisons and real-world effectiveness data remain missing. Until those gaps are filled, the strategy holds promise but still needs stronger evidence.
Unlock the Full original article
You have access to 4 more FREE articles this month.
Click below to unlock and view this original article
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!